You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 241 No. 18, May 4, 1979 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (62)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Proton Radiation as Boost Therapy for Localized Prostatic Carcinoma

William U. Shipley, MD; Joel E. Tepper, MD; George R. Prout, Jr, MD; Lynn J. Verhey, PhD; Oscar A. Mendiondo, MD; Michael Goitein, PhD; Andreas M. Koehler, PhD; Herman D. Suit, MD

JAMA. 1979;241(18):1912-1915.


Abstract

A 160-MeV proton beam has been modified to irradiate patients with localized tumors by using conventional treatment schedules. This proton beam has the physical advantage over megavoltage x-rays of reducing the radiation dose to normal tissues adjacent to the tumor volume. A perineal proton technique used as boost therapy (2,000 to 2,500 rads) was evaluated in the definitive irradiation of 17 patients with localized prostatic carcinoma. This technique allows repeated daily treatment of the carefully defined target volume with a precision of ±2 mm. Total dose to the prostatic tumor, but not to the posterior rectum, has been increased by 500 to 700 rads. After 12 to 27 months of observation, no noteworthy rectal reaction has developed in a patient, easily managed urethral strictures have developed in two patients, and all but one are locally controlled.

(JAMA 241:1912-1915, 1979)



Author Affiliations

From the Departments of Radiation Medicine (Drs Shipley, Mendiondo, Tepper, Verhey, Goitein, and Suit), and Urology (Dr Prout), Massachusetts General Hospital, Harvard Medical School, Boston; and the Cyclotron Laboratory, Harvard University, Cambridge, Mass (Dr Koehler).


Footnotes

Reprint requests to Massachusetts General Hospital, Harvard Medical School, Department of Radiation Medicine, Boston, MA 02114 (Dr Shipley).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

REFERENCES
JOURNAL OF THE ICRU 2007;7:189-210.
 

Phase II Feasibility Study of High-Dose Radiotherapy for Prostate Cancer Using Proton Boost Therapy: First Clinical Trial of Proton Beam Therapy for Prostate Cancer in Japan
Nihei et al.
Jpn J Clin Oncol 2005;35:745-752.
ABSTRACT | FULL TEXT  

Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate: A Randomized Controlled Trial
Zietman et al.
JAMA 2005;294:1233-1239.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1979 American Medical Association. All Rights Reserved.